Zynex files 510(k) application with US FDA for CM1500 for monitoring blood volume
M2 - Thu Sep 24, 5:50AM CDT
Medical technology company Zynex (Other OTC:ZYXI) said on Wednesday that it has filed an 510(k) application with the Food and Drug Administration pursuant to Section 510(k) of the Food, Drug and Cosmetic Act for clearance of its new CM1500 monitoring device.
Zynex, Inc. Announces FDA Filing for Blood Volume Monitor
ACCESSWIRE - Wed Sep 23, 1:56PM CDT
510(K) Application Filed For CM1500 with the Food and Drug Administration
Zynex Announces Second Quarter 2015 Results
Marketwired - Thu Aug 13, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neuro diagnostics, cardiac monitoring and compound pharmacy, announced today its second quarter 2015 financial results.
Zynex Schedules Second Quarter 2015 Earnings Release and Webcast
ACCESSWIRE - Thu Aug 06, 7:01AM CDT
LONE TREE, CO / ACCESSWIRE / August 6, 2015 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it will host the Company's second quarter investor webcast on Thursday, August 13, 2015 at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time.)
Zynex passes DMEPROS programme accreditation upon meeting strict quality, integrity and effectiveness standards
M2 - Thu Jul 02, 8:19AM CDT
Zynex (OtherOTC:ZYXI) revealed on Wednesday that it has received accreditation for its Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) programme from the Accreditation Commission for Health Care.
Zynex Receives DMEPROS Program Accreditation
PRWeb - Wed Jul 01, 8:05AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today it has been awarded accreditation for its Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) program from the Accreditation Commission for Health Care.
Zynex updates Q2 2015 revenue in USD3.2m to USD3.5m range
M2 - Mon Jun 15, 4:43AM CDT
Medical technology company Zynex (OtherOTC:ZYXI) said on Friday that it expects its revenue to be in the range of USD3.2m to USD3.5m for the second quarter ending 30 June 2015.
Zynex Receives Response from FDA on Blood Volume Monitor
GlobeNewswire - Fri Jun 12, 11:22AM CDT
via PRWEB - Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today it has received a response from the FDA concerning the basis for filing its application for approval of its new Blood Volume Monitor. As such, the Company has begun to prepare its request for approval pursuant to Section 510(k) of the Food, Drug and Cosmetic Act.
Zynex Provides Updated Guidance for the Second Quarter 2015
GlobeNewswire - Fri Jun 12, 8:07AM CDT
via PRWEB - Zynex, Inc. (OTCQB:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today it currently expects revenue for the quarter ending June 30, 2015 to be higher than revenue reported in the first quarter of 2015 and be in the range of $3.2 million to $3.5 million. The lower estimate is primarily the result of notification from TRICARE, the health care program for uniformed service members, that it would no longer accept claims related to compound transdermal pain creams.
WEALTHMAKERS.COM: Zynex, Inc. (ZYXI) is Undervalued With Short Term Bullish Patterns and Pending Short Squeeze
M2 - Thu May 21, 10:18AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has initiated coverage today on Zynex Inc. (OTC: ZYXI). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $0.659 and the projected short squeeze valuation of $0.86 per share.
Zynex Receives 44th Pharmacy License Approval
GlobeNewswire - Thu May 21, 7:33AM CDT
via PRWEB - Zynex, Inc. (OTCQB:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it has received license approval from the State of Arkansas for its compound pharmacy business Pharmazy. This brings to 44 the total states, including the District of Columbia, in which the Company is licensed to provide compound pharmacy services.
Zynex Retains BUYINS.NET to Surveil Market Maker and Short Sellers
PRWeb - Tue May 19, 8:10AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics and compound pharmacy, announced today it has retained Buyins.net to initiate coverage and compliance monitoring, short sale trading statistics and market integrity surveillance on its stock. Buyins.net monitors ZYXI market-makers daily for compliance with Fair Market-Making Requirements, and released its first short sale data report on ZYXI on May 14, 2015. The report indicates a SqueezeTrigger price for all ZYXI shares shorted to be $0.66 per share. To view the report or get a more detailed description of the SqueezeTrigger and other indicators, go to http://www.buyins.net and enter "ZYXI" in the search box.
BUYINS.NET Issues Zynex (ZYXI) SqueezeTrigger Report
M2 - Fri May 15, 7:12AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Zynex, Inc. (OTC: ZYXI) after releasing the latest short sale data through May 14, 2015. The total aggregate number of shares shorted since August 2009 is approximately 7.26 million shares. Approximately 36.52% of daily trading volume is short selling. The SqueezeTrigger price for all ZYXI shares shorted is $0.66. A short squeeze is expected to begin when shares of ZYXI close above the $0.66 SqueezeTrigger price.